Full Text View
Tabular View
No Study Results Posted
Related Studies
Efficacy and Safety of Odanacatib in Postmenopausal Women Previously Treated With Alendronate (MK-0822-050)
This study has been withdrawn prior to enrollment.
Study NCT01552122   Information provided by Merck

First Received on March 9, 2012.   Last Updated on June 7, 2012   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Osteoporosis
Postmenopausal Osteoporosis
Additional conditions recognized in this trial
Osteoporosis, Postmenopausal
More general conditions related to this trial
Bone Diseases
Bone Diseases, Metabolic
Musculoskeletal Diseases
Interventions listed in this trial
Odanacatib
Alendronate
Placebo (odanacatib)
Cholecalciferol (Vitamin D3)
Calcium carbonate
Placebo (alendronate)
Additional drug interventions recognized in this trial
Cholecalciferol
Vitamin D
Vitamins
More general drug interventions related to this trial
Antacids
Bone Density Conservation Agents
Growth Substances
Micronutrients
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Sponsors listed in this trial
Merck


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services